Xeljanx, the oral rheumarthritis drug, will receive the insurance benefit from this March

It will now be available to manage rheumarthritisonly with oral drugs2 times.

The Ministry of Health and Welfare had made an administrative notice for the amendment of ‘details regarding application standard and method on medical care expenses’ including information of the Pfizer’s janus kinase (JAX) ‘Xeljanz (tofacitinib)’.In this speed, Xeljanz will be applied on the insurance benefit by thi...